CCT128930, also known as CCT-128930, is a small molecule inhibitor that has been used in research for its potential therapeutic effects. This compound has gained attention for its ability to inhibit the growth of cancer cells, making it a promising candidate for the development of cancer therapies.
Chemical Name: 4-(4-methoxyphenyl)-2-(4-phenylthiazol-2-ylamino)pyrimidine-5-carboxamide
Molecular formula: C23H18N4O2S
Formula weight: 418.48 g/mol
CAS No: 885499-61-6
Top Ten Keywords from Google and Synonyms:
Synonyms: CCT128930, CCT-128930, 885499-61-6
Health Benefits of this Product: The health benefits of CCT128930 remain largely unexplored, as it has primarily been used in laboratory settings for its anti-cancer properties. However, research has shown that the compound can induce apoptosis (cell death) in cancer cells, suggesting that it may have potential as a cancer therapy. Additionally, the compound has been found to inhibit cell proliferation and tumor growth, further supporting its potential as an anti-cancer agent.
Potential Effects: CCT128930 has the potential to be an effective cancer therapy due to its ability to inhibit cell proliferation and induce apoptosis in cancer cells. The compound has been shown to target multiple signaling pathways involved in cancer growth and survival, including the Hsp90 chaperone complex and the PI3K/AKT/mTOR pathway. By inhibiting these pathways, CCT128930 can slow or stop the growth of cancer cells and potentially lead to their destruction.
Product Mechanism: CCT128930 works by inhibiting specific kinases and signaling pathways that are necessary for the survival and growth of cancer cells. The compound has been found to inhibit the Hsp90 chaperone complex, which is involved in stabilizing and folding numerous client proteins that are essential for tumor growth and survival. In addition, CCT128930 has been shown to inhibit the PI3K/AKT/mTOR pathway, which is commonly activated in many types of cancer and promotes cell survival and growth. By targeting these key pathways, CCT128930 disrupts the cellular machinery that allows cancer cells to survive and proliferate.
Safety: As with any experimental drug, the safety of CCT128930 is still being studied. However, initial studies have indicated that the compound is generally well-tolerated in laboratory animals and does not cause significant toxicity or adverse side effects at therapeutic doses. Further studies will be necessary to fully evaluate the safety profile of this compound in humans.
Side Effects: At present, there is limited information available about the potential side effects of CCT128930. However, like other cancer therapies, it is possible that the compound could cause some adverse effects such as nausea, fatigue, and decreased immune function. Future studies will be needed to determine the full range of potential side effects associated with this compound.
Dosing Information: The optimal dosing of CCT128930 for human patients has not yet been established, as the compound is still in the early stages of preclinical development. However, laboratory studies have used doses ranging from 0.1 to 10 μM, depending on the specific experiments being conducted. It is likely that future clinical trials will investigate various dosing regimens to determine the most effective and safe dose for treating cancer in humans.
Conclusion: CCT128930 is a promising small molecule inhibitor with potential as a cancer therapy. Its ability to inhibit key signaling pathways that promote cancer growth and survival makes it an attractive target for drug development. While more studies are needed to determine the safety and efficacy of this compound, initial results suggest that CCT128930 could be an important tool in the fight against cancer.